Research
Hormonal
GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produce significant, sustained weight reduction in adults with obesity by acting on the gut-brain axis to reduce appetite and food intake.
Semaglutide 2.4 mg injected once weekly, combined with lifestyle counseling, leads to an average 14.9% body weight loss in adults with obesity over 68 weeks. Side effects like nausea are common initially but typically subside; starting with a lower dose helps manage this.
StrongSupportsVERY_HIGH confidence
GLP-1 receptor agonists (GLP-1 RAs) represent the first agents in a rapidly evolving, highly promising landscape of nascent hormone-based obesity therapeutics... GLP-1 RAs can be deployed as monotherapy... These emerging entero-endocrine and endo-pancreatic agents combined or coformulated with GLP-1 RAs herald a new era of targeted, mechanism-based treatment of obesity.
Why this rating
Based on multiple Phase III randomized double-blind placebo-controlled trials (SCALE, STEP, SURMOUNT) with large sample sizes.
Source
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff et al. · Annual Review of Medicine · 2023
narrative_reviewCited 148×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →